|Ms. Saundra Pelletier||Pres, CEO & Director||1.91M||N/A||1970|
|Mr. Justin J. File||Chief Financial Officer||886.51k||N/A||1970|
|Mr. Russell Barrans||Chief Commercial Officer||678.57k||N/A||1960|
|Mr. Richard Murawski||Sr. VP of Operations||N/A||N/A||1948|
|Mr. Mark Kowieski||VP of Fin. & Accounting||N/A||N/A||N/A|
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Evofem Biosciences, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 10; Compensation: 9.